(NASDAQ: RVPH) Reviva Pharmaceuticals Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.27%.
Reviva Pharmaceuticals Holdings's earnings in 2025 is -$27,111,725.On average, 2 Wall Street analysts forecast RVPH's earnings for 2025 to be -$32,981,752, with the lowest RVPH earnings forecast at -$35,361,879, and the highest RVPH earnings forecast at -$30,601,626. On average, 2 Wall Street analysts forecast RVPH's earnings for 2026 to be -$22,101,174, with the lowest RVPH earnings forecast at -$22,441,192, and the highest RVPH earnings forecast at -$21,761,156.
In 2027, RVPH is forecast to generate -$10,880,578 in earnings, with the lowest earnings forecast at -$10,880,578 and the highest earnings forecast at -$10,880,578.